文献速递糖尿病

恩格列净辅助胰岛素治疗1型糖尿病:EASE试验

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
PubMed 文献 · Diabetes Care · 2018-10-04

EASE项目包含两项双盲安慰剂对照3期试验,评估恩格列净2.5、10、25 mg辅助强化胰岛素治疗1型糖尿病的安全性与疗效。结果显示各剂量均降低糖化血红蛋白和体重、增加葡萄糖目标范围内时间、减少胰岛素剂量,且不增加低血糖,但10和25 mg剂量糖尿病酮症酸中毒发生率高于安慰剂。

要点

  • 恩格列净2.5/10/25 mg均显著降低HbA1c、体重和胰岛素剂量。
  • 10和25 mg剂量增加糖尿病酮症酸中毒风险,2.5 mg与安慰剂相当。
  • 需监测酮体以早期发现和干预酮症酸中毒,较低剂量可能降低风险。

核心结论

  • 恩格列净改善1型糖尿病患者的血糖控制和体重,且不增加低血糖。
  • 酮症酸中毒发生率在2.5 mg与安慰剂间相当,但10 mg和25 mg剂量升高。

研究设计与样本

  • EASE项目共纳入1707例1型糖尿病患者。
  • EASE-2为52周治疗,恩格列净10 mg(n=243)、25 mg(n=244)与安慰剂(n=243)。
  • EASE-3为26周治疗,恩格列净2.5 mg(n=241)、10 mg(n=248)、25 mg(n=245)与安慰剂(n=241)。

主要发现

  • 安慰剂校正的糖化血红蛋白最大降幅:2.5 mg为-0.28%(95%CI -0.42, -0.15),10 mg为-0.54%(-0.65, -0.42),25 mg为-0.53%(-0.65, -0.42),均P<0.0001。
  • 2.5/10/25 mg分别降低平均体重-1.8/-3.0/-3.4 kg(均P<0.0001)。
  • 2.5/10/25 mg分别增加葡萄糖目标范围内时间+1.0/+2.9/+3.1 h/day(10和25 mg P<0.0001)。
  • 2.5/10/25 mg分别降低每日总胰岛素剂量-6.4/-13.3/-12.7%(均P<0.0001)。
  • 2.5/10/25 mg分别降低收缩压-2.1/-3.9/-3.7 mmHg(均P<0.05)。

关键数值与推荐

  • 生殖器感染在恩格列净组更常见。
  • 经判定的糖尿病酮症酸中毒发生率:恩格列净10 mg为4.3%,25 mg为3.3%,2.5 mg为0.8%,安慰剂为1.2%。
  • 严重低血糖罕见,恩格列净与安慰剂组频率相似。

临床怎么用

  • 恩格列净可作为1型糖尿病强化胰岛素的辅助治疗以改善血糖和体重。
  • 使用恩格列净时需监测酮体以及早发现和干预酮症酸中毒。
  • 较低剂量(2.5 mg)可能有助于降低酮症酸中毒风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of empagliflozin 10- and 25-mg doses plus a unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The EASE (Empagliflozin as Adjunctive to inSulin thErapy) program (N = 1,707) included two double-blind, placebo-controlled phase 3 trials: EASE-2 with empagliflozin 10 mg (n = 243), 25 mg (n = 244), and placebo (n = 243), 52-week treatment; and EASE-3 with empagliflozin 2.5 mg (n = 241), 10 mg (n = 248), 25 mg (n = 245), and placebo (n = 241), 26-week treatment. Together they evaluated empagliflozin 10 mg and 25 mg, doses currently approved in treatment of type 2 diabetes, and additionally 2.5 mg on 26-week change in glycated hemoglobin (primary end point) and weight, glucose time-in-range (>70 to ≤180 mg/dL), insulin dose, blood pressure, and hypoglycemia. RESULTS: The observed largest mean placebo-subtracted glycated hemoglobin reductions were -0.28% (95% CI -0.42, -0.15) for 2.5 mg, -0.54% (-0.65, -0.42) for 10 mg, and -0.53% (-0.65, -0.42) for 25 mg (all P < 0.0001). Empagliflozin 2.5/10/25 mg doses, respectively, reduced mean weight by -1.8/-3.0/-3.4 kg (all P < 0.0001); increased glucose time-in-range by +1.0/+2.9/+3.1 h/day (P < 0.0001 for 10 and 25 mg); lowered total daily insulin dose by -6.4/-13.3/-12.7% (all P < 0.0001); and decreased systolic blood pressure by -2.1/-3.9/-3.7 mmHg (all P < 0.05). Genital infections occurred more frequently on empagliflozin. Adjudicated diabetic ketoacidosis occurred more with empagliflozin 10 mg (4.3%) and 25 mg (3.3%) but was comparable between empagliflozin 2.5 mg (0.8%) and placebo (1.2%). Severe hypoglycemia was rare and frequency was similar between empagliflozin and placebo. CONCLUSIONS: Empagliflozin improved glycemic control and weight in T1D without increasing hypoglycemia. Ketoacidosis rate was comparable between empagliflozin 2.5 mg and placebo but increased with 10 mg and 25 mg. Ketone monitoring for early ketoacidosis detection and intervention and lower empagliflozin doses may help to reduce this risk.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care. 2018. PMID: 30287422. doi:10.2337/dc18-1749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。